Biotest hosts first international symposium to increase awareness for cytomegalovirus infections
- More than 125 participants from over 21 countries and 3 continents discussed about severe complications of a cytomegalovirus (CMV) infection in solid organ transplantation, stem cell transplantation and CMV-infection in pregnant women
- Guideline for organ transplantation opens new market potentials for Biotest's CMV hyperimmunoglobulin
- Biotest is the only provider of anti-CMV hyperimmunoglobulin outside North America and Australia
Dreieich, 17 December 2019. Biotest AG successfully hosted the first international symposium specifically dedicated to the impact of CMV and its treatment in immunosuppressed patients. Usually, patients after organ transplantation receive therapy to supress the immune system in order to prevent organ rejection. In those patients, a CMV-infection can cause severe complications. Besides others, one possible option to prevent CMV infection is the use of CMV hyperimmunoglobulins. Biotest is one of only two providers of this class of anti-CMV drug worldwide.
Together with the scientific coordinators, Prof Juliàn de la Torre and Dr Piedad Ussetti, Biotest facilitated a two-day program featuring international key opinion leaders. At the event, newest scientific insights and options to prevent CMV infections in patients, who received a solid organ or a stem cell transplantation as well as in pregnant women with CMV infection were discussed. Delegates from 21 countries and 3 continents engaged in discussing and exchanging experiences during these symposium. During this meeting, a huge interest for the use of CMV hyperimmunoglobulins to prevent CMV-related complications was shown.
Dr Piedad Ussetti presented new transplantation guidelines, which will influence the number of available organs in the future, thus increasing the number of patients potentially suffering from CMV-related complications.
Biotest will build upon this successful first event and use the momentum to continue increasing the awareness for all treatment options and the use of CMV hyperimmunoglobulins.
Biotest recently received approval in 12 selected attractive European markets. This will further increase the market potential and strengthen Biotest's position for this life-saving and high margin product.
By facilitating the international symposium, Biotest intends to increase awareness for the threat posed by CMV infections in immunocompromised patients.
About Cytotect(R) CP Biotest
Cytotect(R) CP Biotest is a cytomegalovirus (CMV)-specific hyperimmunoglobulin preparation with a high antibody titre against CMV. The product is approved for prophylaxis of clinical manifestations of CMV infection in patients subjected to immunosuppressive therapy, particularly in transplant recipients. The concomitant use of adequate virostatic agents should be considered for CMV-prophylaxis.
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,800 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
Dr Monika Buttkereit
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
17.12.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de